# Supported breastfeeding among women with diagnosed HIV in the UK- the current picture

Kate Francis, Claire Thorne, <u>Rebecca Sconza</u>, Anna Horn, Helen Peters

Population, Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health

# Background

- The HIV vertical transmission (VT) rate was 0.28% (95% CI 0.08%, 0.71%) among births to diagnosed women living with HIV (WLHIV) in the UK and Ireland in 2015-2016
- The British HIV Association (BHIVA) recommends formula-feeding infants born to WLHIV to eliminate risk of postnatal transmission but states that virologically-suppressed treated women with good adherence wishing to breastfeed may be clinically supported to do so (see BHIVA guidelines, right))

### BHIVA 2018 guidelines for management of supported BF

Happy tums

Diarrhoea and vomiting show that a

tummy is irritated. If your baby's tummy is

irritated it may be more likely that HIV will

paby. If your tummy is irritated you may

not absorb your HIV medication properly.

Only breastfeed if both of you have a

happy tumm

cross into the blood steam and infect your

#### No virus If the HIV virus in your blood is detectable, there will be HIV in your breast milk, and HIV will enter your baby's body on feeding. You should only breastfeed your baby if your HIV is undetectable.

Healthy breasts for mums

There may be HIV in your breast milk if your nipples are cracked or bleeding, or if you have thrush, develop an infection or have mastitis. Only breastfeed if your breasts are healthy.

### The Safer Triangle means:

No Virus + Happy Tums + Healthy Breasts for Mums

Mother and infant should be reviewed monthly for HIV RNA testing during BF and for two months after stopping BF

**[P118]** 

- Maternal cART rather than infant pre-exposure prophylaxis advised
- Infant HIV antibody testing for seroreversion at age 18-24 months
- BF for as short a time as possible
- exclusively for the first 6 months

 The objective of this work was to estimate the prevalence of breastfeeding (BF) among WLHIV in the UK and describe current clinical practice

# Methods

- National Surveillance of HIV in Pregnancy and Childhood (NSHPC) is part of Public Health England's Infectious Diseases in Pregnancy Screening Programme
- All pregnancies to women living with HIV in the UK/Ireland are actively reported, along with their HIV-exposed infants and any children diagnosed with HIV (<16yrs age)</li>
- Data on supported breastfeeding has been collected since 2012
- Enhanced surveillance of mother-infant pairs where BF was reported (planned/occurred) since August 2018
- Eligible population: livebirth deliveries to diagnosed women 2012-19

#### ....

#### Figure 1. The Safer Triangle

Source: BHIVA Patient breastfeeding information leaflet 2: General information on infant feeding for women living with HIV, available at www.bhiva.org/file/5bfd308d5e189/BF-Leaflet-2.pdf



 cease if: signs of breast infection/mastitis, mother or infant has gastrointestinal symptoms or if maternal virus becomes detectable (the Safer Triangle)

Source: BHIVA guidelines on the management of HIV in pregnancy and postpartum 2018 (2019 interim update), available at www.bhiva.org/pregnancy-guidelines

### **NSHPC enhanced data collection**

**Enhanced surveillance:** additional data collected by phone for **all reported cases of planned/supported breastfeeding** from NSHPC paediatric and maternity respondents. Questions included:

- Reasons for wanting to breastfeed
- Whether the woman's partner and GP knew her HIV status
- Duration of breastfeeding
- Whether any mixed feeding occurred before 6 months of age
- Maternal and infant test results during breastfeeding
- Maternal cART during breastfeeding
- Infant confirmatory antibody tests (18-24 months)



of HIV in



### Results

# Among 7187 livebirth deliveries, 135 (1.9%) were reported as planned and/or supported to breastfeed

- 93% (125/135) were births to women diagnosed before pregnancy
- 83% (112/135) were pregnancies to women born abroad
- 13% (18/135) were in women supported to BF >1 infant
- Median maternal age at delivery was 35 years (IQR: 31,40)

Enhanced data collection on 102 supported BF cases: BF ongoing in 9/102 and 3/102 were lost to follow-up.

Current case status among cases where BF was reported to have stopped (90/102):



In 4/90, BF was reported to have stopped due to maternal VL rebound

- > 2 confirmed negative
- » 2 awaiting confirmatory antibody

In 3/90, ≥1 detectable VL was reported during BF period

» 1 had negative antibody



- Duration of BF ranged from 1 day to 2 years; median duration: 7 weeks (IQR: 3, 16)
- Reasons for stopping BF included: part of a plan to stop (36), mastitis

Negative antibody test
Lost to followup

**Figure 2: Infant follow-up** (where BF stopped), *n* = 90

- » 1 still in follow-up
- » 1 lost to follow-up
- (3), VL rebound (4), problems latching (6), hospitalisation of mother and/or infant (2)
- Mixed feeding before 6 months of age in 10/90 cases
- Mastitis reported in two cases where breastfeeding continued

### Conclusions

**BF reports reflect guideline updates, the current 'U=U' era and continued strides towards normalising maternity experiences for WLHIV**. Cases to date have been few but diverse, underscoring the **need for careful monitoring to allow early identification and management of VL blips**. Although results show no VTs among supported BF cases so far, a postnatal transmission likely attributable to covert BF by a woman who had undetectable VL throughout pregnancy was reported in 2016. Further insights enabled by national surveillance have the potential to guide policy and practice.

Funding and ethics	Acknowledgements	Contact	National Surveillance
The NSHPC currently receives funding from Public Health England's Infectious Diseases	Many thanks to everyone who reports to the NSHPC, the current NSHPC team, and the	www.ucl.ac.uk/nshpc	NCLI
in Pregnancy Screening (IDPS) Programme.	IDPS team headed by Sharon Webb	k.francis@ucl.ac.uk	NJUL
London Multi-Centre Research Ethics Committee approval MREC/04/2009.	Any views expressed are those of the authors and not necessarily those of the funders	MSHPC_UCL	Pregnancy and Chi